RT期刊文章SR电子T1识别和治疗长期发热性癫痫;从FEBSTAT研究的结果(- 2.005)把摩根富林明神经病学神经学乔FD Lippinc首页ott Williams &威尔金斯SP - 2.005 OP - 2.005签证官把鱼把鱼78 1补充A1 Syndi宋飞A1约翰Pellock A1什洛莫Shinnar A1戴尔Hesdorffer A1露丝Shinnar A1凯瑟琳·奥哈拉A1道格拉斯Nordli A1威廉·l·弗兰克A1 Gallentine A1所罗门Moshe A1晓燕邓A1捧阳光年2012 UL //www.ez-admanager.com/content/78/1_Supplement/IN5-2.005.abstract AB目的:分析院前和急诊科(ED)承认发热性癫痫发作和治疗发热性癫痫持续状态(FSE)。背景被识别和及时的治疗是很重要的。设计/方法:200名受试者的孩子1个月到5年的前瞻性多中心研究工程师协会的后果,定义为一系列发热性癫痫发作或发作持续> 30分钟。工程师协会是由3个独立的中央分类评级机构,完全基于临床特征。紧急医疗服务(EMS)和教育管理,包括癫痫识别、药物管理和呼吸支持,综述。结果:46名受试者(23%)没有激活EMS。154名受试者被EMS运输,12(8%)没有抓住EMS到达时,24例(16%)患者的临床状况没有文档。118受试者积极抓住EMS到来,81%(96例)被EMS。在EMS运输,9(6%)没有积极抓住主题。EMS公认扣押在运输期间83名患者(54%)。的抗癫痫药物(AED)是73年由家庭/ EMS科目(37%)。 19 of the 154 patients (12%) were given respiratory support by EMS. 167 subjects (84%) were actively seizing on ED arrival. ED recognized the seizure in 163 subjects (98%). 91 of 200 subjects (46%) were given respiratory support by the ED. 150 subjects (75%) required an AED to terminate seizure. Mean time from seizure onset to first AED was 55 minutes (3 minutes to 465 minutes).Conclusions: Febrile status epilepticus is a neurological emergency requiring prompt recognition and treatment. The majority of children with prolonged febrile seizures required abortive medications to terminate their seizures, which were very prolonged. Although the majority of seizures are recognized, there is a considerable delay in administration of first AED.Supported by: Grant NS 43209 (PI: S Shinnar MD PhD) from NINDS.Disclosure: Dr. Seinfeld has nothing to disclose. Dr. Pellock has received personal compensation for activities with NIH/NINDS, Eisai, GSK, King Pharmaceuticals, KV Pharmaceuticals, Marinus Pharmaceuticals, Neuropace, Ortho McNeil Johnson&Johnson, Lundbeck, Pfizer, Questcor, Sepracor, UCB Pharmaceuticals, and Valeant as an advisory board member, consultant, or lecturer. Dr. Pellock has received research support from NIH/NINDS, Eisai, GSK, Lundbeck, Pfizer, Questcor, UCB Pharmaceuticals, and Valeant. Dr. Shinnar has received personal compensation for activities with Design Write, Eisai, Inc., King Pharmaceuticals, Questcor Pharmaceuticals, Valeant Pharmaceuticals, and UCB Pharma. Dr. Shinnar has received research support from Questcor Pharmaceuticals. Dr. Hesdorffer has nothing to disclose. Dr. Shinnar has nothing to disclose. Dr. O'Hara has received personal compensation for activities with Cyberonics and Questcor as a speaker and/or serving on an advisory board. Dr. Nordli has received personal compensation in an editorial capacity for UpToDate. Dr. Nordli has received research support from NIH/NINDS. Dr. Frank has nothing to disclose. Dr. Gallentine has nothing to disclose. Dr. Moshe has received personal compensation for activities with Eisai and GlaxoSmithKline. Dr. Moshe has received personal compensation in an editorial capacity for Neurobiology of Disease, Epileptic Disorders, and Brain and Development and Physiological Research. Dr. Moshe has received research support from NIH and the Heffer Family Foundation. Dr. Deng has nothing to disclose. Dr. Sun has nothing to disclose.Monday, April 23 2012, 14:00 pm-18:00 pm